NDA 209963 · Lxo Ireland
Goprelto
Cocaine Hydrochloride · Nasal
Last checked: Nov 20, 2026Latest source record: Jul 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
Dec 14, 2017
Approved uses
1
Original approval plus efficacy supplements
Registered trials
415
35 Phase 3, 16 recruiting
FAERS reports
381
370 serious, 245 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence [see Warning and Precautions (5.1) . ] WARNING: ABUSE AND DEPENDENCE See full prescribing information for complete boxed warning. CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (5.1)
What it is approved for
From the label in effect Nov 6, 2024.
GOPRELTO (cocaine hydrochloride) nasal solution is indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults. GOPRELTO (cocaine hydrochloride) nasal solution is an ester local anesthetic indicated for the induction of local anesthesia of the mucous membranes when performing diagnostic procedures and surgeries on or through the nasal cavities in adults. ( 1 )
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- GOPRELTO · COCAINE HYDROCHLORIDE 4% · SOLUTION, NASAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cocaine" as an intervention, any sponsor and status, largest first.
- Trial of Modifications to Radical ProstatectomyPivotal-lookingActive, not recruiting
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
NCT01407263 · 3,204 participants · Start Jul 2011 · Primary completion Jul 2027
Drug: antibiotic prophylaxis; Hemostatic Agent · For: Prostate Cancer
Sites: Basking Ridge, New Jersey; Montvale, New Jersey; Harrison, New York · 5 sites in all
- A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of AgePivotal-lookingCompleted
MedImmune LLCAstraZeneca (AZN)
NCT00952705 · 1,800 participants · Start Aug 2009 · Primary completion Jan 2010
Drug: Q/LAIV-BFS (MEDI8662); FluMist/B/Yamagata and 1 more · For: Healthy or Stable Underlying Chronic Medical Condition
Sites: Mobile, Alabama; Sacramento, California; San Diego, California · 18 sites in all
- Topical Application of Cocaine HCl 4%, or 10%, or Placebo Solution in Local (Topical) AnesthesiaPivotal-lookingCompleted
Lannett Company, Inc.Industry
NCT02500836 · 646 participants · Start Sep 2015 · Primary completion Jul 2016
Drug: Cocaine HCl 4% Topical Solution; Cocaine HCl 10% Topical Solution and 1 more · For: Any Ear Nose or Throat Conditions; With Identified Need for a Diagnostic Procedure or Surgery on or Through the Mucous Membranes of the Nasal Cavities
Sites: Richmond, Virginia
- Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung CancerPivotal-lookingActive, not recruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT03059940 · 630 participants · Start Jun 16, 2017 · Primary completion Jan 15, 2027
Drug: Nicotine Patch; Anti-Smoking Drug · For: Smoking Cessation
Sites: Houston, Texas
- Adaptive Treatment for Alcohol and Cocaine DependencePivotal-lookingCompleted
University of PennsylvaniaAcademic, hospital or other
NCT01032135 · 500 participants · Start Oct 2008 · Primary completion Dec 2013
Drug: medication management · For: Substance Use Disorders
Sites: Philadelphia, Pennsylvania · 3 sites in all
- Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)Pivotal-lookingCompleted
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT05262270 · 427 participants · Start Apr 18, 2023 · Primary completion Jun 27, 2025
Drug: Extended-Release Naltrexone; Extended Release Buprenorphine and 2 more · For: Cocaine Use Disorder
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 12 sites in all
National Institute on Drug Abuse (NIDA)NIH
NCT00000218 · 353 participants
Drug: Carbamazepine · For: Cocaine-Related Disorders; Substance-Related Disorders
Sites: Kansas City, Missouri
- Cocaine Use Reduction With BuprenorphinePivotal-lookingCompleted
University of California, Los AngelesAcademic, hospital or other
NCT01402492 · 302 participants · Start Sep 2011 · Primary completion Jan 2013
Drug: Buprenorphine + Naltrexone; Placebo + Naltrexone · For: Cocaine Dependence
Sites: Los Angeles, California; San Francisco, California; Denver, Colorado · 11 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- completed suicide95
- cardiac arrest91
- respiratory arrest86
- drug abuse52
- toxicity to various agents47
- poisoning deliberate38
- product use issue38
- death29
- suicidal ideation23
- drug dependence21
- suspected suicide20
- intentional product misuse19
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 3 |
| 2011 | 2 |
| 2012 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 13 |
| 2018 | 19 |
| 2019 | 30 |
| 2020 | 57 |
| 2021 | 49 |
| 2022 | 47 |
| 2023 | 47 |
| 2024 | 36 |
| 2025 | 54 |
| 2026 | 12 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.
Chan B, Kondo K, Freeman M, et al. · J Gen Intern Med 2019 · Meta-Analysis, Research Support, U.S. Gov't, Non-P.H.S.
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.
Tardelli VS, Bisaga A, Arcadepani FB, et al. · Psychopharmacology (Berl) 2020 · Meta-Analysis, Systematic Review
- Anticonvulsants for cocaine dependence.
Minozzi S, Cinquini M, Amato L, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Antipsychotic medications for cocaine dependence.
Indave BI, Minozzi S, Pani PP, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Influence of cocaine use reduction on markers of immune function.
Stoops WW, Shellenberg TP, Regnier SD, et al. · J Neuroimmunol 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
- Substance use and spine density: a systematic review and meta-analysis of preclinical studies.
Oliva HNP, Prudente TP, Nunes EJ, et al. · Mol Psychiatry 2024 · Systematic Review, Meta-Analysis
Sponsor: Lxo Ireland
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.